(919) 351-6541
FDA WARNING LETTER RESPONSE — LED BY FORMER SITE LEADERS

When a warning letter arrives, we are your next call.

Response and advisory from Senior Quality & Regulatory executives who have led 500+ observation-free regulatory inspections and consent-decree recovery programs for top global biopharma companies. We know FDA, EMA, and biopharma manufacturing — and how to help you get back to delivering lifesaving solutions. Confidential response. Immediate support available. First call is free.

Speak with a Senior Regulatory Expert in less than 24 hours
  • Pfizer
  • Johnson & Johnson
  • Abbott
  • Bristol Myers Squibb

Request a Confidential Consultation

Takes 60 seconds 100% confidential

  • FDA Form 483 / observation letter
  • FDA Warning Letter
  • Inspection pending or underway
  • CAPA or remediation program
  • GMP audit / mock inspection
  • 510(k) / PMA / de novo submission
  • Other quality / regulatory work
  • We have an active letter — need help fast
  • Inspection coming in the next 30 days
  • Preparing proactively, no active issue
  • Exploring options

Request Received

Thank you. A senior advisor will contact you within one business day. Your information is held in strict confidence.

100% Secure & Confidential
Selected Services Offered

Focused response for the work on your desk now

Three high-pressure engagement paths for FDA observations, Warning Letters, and sustained remediation.

FDA 483 Response

Structured, agency-ready responses that address root cause — not just the observation on the page.

Warning Letter Remediation

End-to-end remediation programs built to withstand the follow-up inspection, not just close to the letter.

Consent Decree Recovery

Sustained operational and compliance transformation to meet decree requirements — and exit them.

The Practice

Proven where it matters: under regulatory pressure.

500+
Regulatory inspections supported, with responses that hold under FDA scrutiny
200+
New product launches delivered without regulatory disruption
13
Global regulatory bodies navigated, including FDA, EMA, and others
15
Business days to structure an FDA Warning Letter response. We mobilize immediately.
In Good Company

Trusted by life-sciences companies where failure isn’t an option.
We’ve supported organizations facing the same regulatory pressure you are, including global manufacturers and complex multi-site environments.

  • Baxter
  • Edwards Lifesciences
  • Clorox
  • MCS Healthcare
  • Evertec
Why LaSalle

Why Quality & Regulatory Leaders Bring in LaSalle

Senior operators, regulatory realism, and agency-ready responses built to hold up under follow-up inspection.

Senior Operators, Not Advisors

You work directly with leaders who have managed FDA inspections from inside manufacturing sites, not junior teams learning on your timeline.

Built for Regulatory Reality

We don’t just respond to observations. We identify what caused them and stabilize the system behind them, so findings don’t repeat.

Designed to Hold Up Under Inspection

Responses are structured to withstand follow-up inspections, not just close to the letter.

Enterprise Experience Without Bureaucracy

We operate at the level of global consulting firms, without delays, layers, or generic playbooks.

Global Regulatory Coverage

We navigate FDA, EMA, MHRA, and other global regulatory bodies for organizations managing compliance across multiple sites and regions.

Start the Conversation

If You’re Holding an FDA 483 or Warning Letter — Don’t Delay

Early response decisions determine whether issues are contained or expanded. Speak directly with a senior practitioner. Call now for a confidential discussion or request a consultation in under a minute.

(919) 351-6541 or Fill out the form above